
    
      This Continued Access Protocol is a prospective, non-randomized, multicenter study to allow
      continued access to the WATCHMAN LAA Closure Technology during the data analysis, reporting
      and review of the PREVAIL pivotal study Pre-Market Application by FDA.
    
  